Peter Kolchinsky‘s RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently gone public, Protagonist Therapeutics Inc (NASDAQ:PTGX). The new stake consists of 1.11 million common shares, which amass 6.8% of the company’s outstanding stock.
Protagonist Therapeutics Inc (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that is working on discovering and manufacturing peptide-based new chemical entities for treatment of unresolved medical conditions. Recently, the company gained SBIR Funding for the development of Injectable Hepcidin Mimetics for the treatment of iron overload disorders. Since the company started trading on August 12, its stock has lost 8.46%.
RA Capital is the second fund in our database to have revealed taking a large stake in the newly-public company; Phill Gross and Robert Atchinson’s Adage Capital Management reported owning 1.58 million shares of the company last week, with the position representing 9.69% of Protagonist Therapeutics Inc (NASDAQ:PTGX)’s stock.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|RA Capital Management||0||1,109,229||0||1,109,229||1,109,229||6.8%|
|RA Capital Healthcare Fund||0||909,203||0||909,203||909,203||5.6%|
Page 1 of 7 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of
(Amendment No. __)*
Protagonist Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per
(Title of Class of Securities)
August 16, 2016
(Date of Event Which Requires Filing of
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).